Please wait a minute...
J Zhejiang Univ (Med Sci)  2021, Vol. 50 Issue (6): 783-794    DOI: 10.3724/zdxbyxb-2021-0072
Research progress on inflammatory mechanism of primary Sj?gren syndrome
REN Yuan,CUI Gedan,GAO Yongxiang()
School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
Download: HTML( 13 )   PDF(2191KB)
Export: BibTeX | EndNote (RIS)      


Primary Sj?gren syndrome is an autoimmune disease, in which a large number of lymphocytes infiltrate the exocrine glands and cause gland dysfunction. Its pathogenesis is related to the chronic inflammation of the exocrine glands caused by genetic factors, immunodeficiency or viral infection. Long-term inflammation leads to accelerated apoptosis of epithelial cells, disordered gland structure, increased expression of proinflammatory cytokine such as CXC subfamily ligand (CXCL) 12, CXCL13, B cell-activating factor (BAF), interleukin (IL)-6, interferon (IFN)-γ and tumor necrosis factor (TNF)-α in submandibular gland. With the action of antigen-presenting cells such as dendritic cells and macrophages, lymphocytes (mainly B cells) are induced to mature in secondary lymphoid organs and migrate to the submandibular gland to promotes the formation of germinal centers and the synthesis of autoantibodies. Meanwhile, innate lymphocytes, vascular endothelial cells and mucosa-associated constant T cells as important immune cells, also participated in the inflammatory response of the submandibular gland in primary Sj?gren syndrome through different mechanisms. This process involves the activation of multiple signal pathways such as JAK/STAT, MAPK/ERK, PI3K/AKT/mTOR, PD-1/PD-L1, TLR/MyD88/NF-κB, BAF/BAF-R and IFN. These signaling pathways interact with each other and are intricately complex, causing lymphocytes to continuously activate and invade the submandibular glands. This article reviews the latest literature to clarify the mechanism of submandibular gland inflammation in primary Sj?gren syndrome, and to provide insights for further research.

Key wordsPrimary Sj?gren syndrome      Submandibular gland      Immunocytes      Inflammatory response mechanisms      Signaling pathway      Review     
Received: 16 March 2021      Published: 22 March 2022
CLC:  R593.2  
Corresponding Authors: GAO Yongxiang     E-mail:
Cite this article:

REN Yuan,CUI Gedan,GAO Yongxiang. Research progress on inflammatory mechanism of primary Sj?gren syndrome. J Zhejiang Univ (Med Sci), 2021, 50(6): 783-794.

URL:     OR



关键词: 原发性干燥综合征,  颌下腺,  免疫细胞,  炎症机制,  信号通路,  综述 
[1]   SJ?GREN H. Zur kenntnis der keratoconjunctivitis sicca. Ⅲ[J]Acta Ophthalmologica, 2009, 13( 1-2): 40-45.
doi: 10.1111/j.1755-3768.1935.tb04187.x
[2]   QIN B, WANG J, YANG Z, et al.Epidemiology of primary Sj?gren’s syndrome: a systematic review and meta-analysis[J]Ann Rheum Dis, 2015, 74( 11): 1983-1989.
doi: 10.1136/annrheumdis-2014-205375
[3]   AKPEK E K, BUNYA V Y, SALDANHA I J. Sj?gren’s syndrome: more than just dry eye[J]Cornea, 2019, 38( 5): 658-661.
doi: 10.1097/ICO.0000000000001865
[4]   ALAM J, LEE A, LEE J, et al.Dysbiotic oral microbiota and infected salivary glands in Sj?gren’s syndrome[J/OL]PLoS One, 2020, 15( 3): e0230667.
doi: 10.1371/journal.pone.0230667
[5]   GONGY Z, NITITHAMJ, TAYLORK, et al.Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sj?gren’s syndrome[J]J Autoimmunity, 2014, 57-66.
doi: 10.1016/j.jaut.2013.11.003
[6]   MANOUSSAKIS M N, SPACHIDOU M P, MARATHEFTIS C I. Salivary epithelial cells from Sjogren’s syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation[J]J Autoimmunity, 2010, 35( 3): 212-218.
doi: 10.1016/j.jaut.2010.06.010
[7]   CROW M K. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease[J]Autoimmunity, 2010, 43( 1): 7-16.
doi: 10.3109/08916930903374865
[8]   SENFT D, RONAI Z’ A. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response[J]Trends Biochem Sci, 2015, 40( 3): 141-148.
doi: 10.1016/j.tibs.2015.01.002
[9]   HILLEN M R, VERVERS F A, KRUIZE A A, et al.Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sj?gren’s syndrome[J]Expert Rev Clin Immunol, 2014, 10( 4): 521-531.
doi: 10.1586/1744666X.2014.878650
[10]   DU B, ZHU M, LI Y, et al.The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis[J/OL]Scand J Immunol, 2020, 91( 5): e12872.
doi: 10.1111/sji.12872
[11]   REIZIS B. Plasmacytoid dendritic cells: development, regulation, and function[J]Immunity, 2019, 50( 1): 37-50.
doi: 10.1016/j.immuni.2018.12.027
[12]   SHEN L, SURESH L, MALYAVANTHAM K, et al.Different stages of primary Sj?gren’s syndrome involving lymphotoxin and type 1 IFN[J]J Immunol, 2013, 191( 2): 608-613.
doi: 10.4049/jimmunol.1203440
[13]   HOOPER K M, YEN J H, KONG W, et al.Prostaglandin E2 inhibition of IL-27 production in murine dendritic cells: a novel mechanism that involves IRF1[J]J Immunol, 2017, 198( 4): 1521-1530.
doi: 10.4049/jimmunol.1601073
[14]   SAITOH S I, ABE F, KANNO A, et al.TLR7 mediated viral recognition results in focal type Ⅰ interferon secretion by dendritic cells[J]Nat Commun, 2017, 8( 1): 1592.
doi: 10.1038/s41467-017-01687-x
[15]   VERSTAPPEN G M, CORNETH O B J, BOOTSMA H, et al.Th17 cells in primary Sj?gren’s syndrome: pathogenicity and plasticity[J]J Autoimmunity, 2018, 16-25.
doi: 10.1016/j.jaut.2017.11.003
[16]   CHAUDHARI S, KUMAR M S. Marine sponges Sarcotragus foetidus, Xestospongia carbonaria and Spongia obscura constituents ameliorate IL-1β and IL-6 in lipopolysaccharide-induced RAW 264.7 macrophages and carrageenan-induced oedema in rats[J]Inflammopharmacology, 2020, 28( 4): 1091-1119.
doi: 10.1007/s10787-020-00699-2
[17]   CHRISTODOULOU M I, KAPSOGEORGOU E K, MOUTSOPOULOS H M. Characteristics of the minor salivary gland infiltrates in Sj?gren’s syndrome[J]J Autoimmunity, 2010, 34( 4): 400-407.
doi: 10.1016/j.jaut.2009.10.004
[18]   ZHOU D, MCNAMARA N A. Macrophages: important players in primary Sj?gren’s syndrome?[J]Expert Rev Clin Immunol, 2014, 10( 4): 513-520.
doi: 10.1586/1744666X.2014.900441
[19]   KANG J K, HYUN C G. 4-Hydroxy-7-methoxycoumarin inhibits inflammation in LPS-activated RAW264.7 macrophages by suppressing NF-κB and MAPK activation[J]Molecules, 2020, 25( 19): 4424.
doi: 10.3390/molecules25194424
[20]   ROVATI L, KANEKO N, PEDICA F, et al.Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease[J]Rheumatology, 2021, 60( 10): 4929-4941.
doi: 10.1093/rheumatology/keab096
[21]   WITAS R, PECK A B, AMBRUS J L, et al.Sj?gren’s syndrome and TAM receptors: a possible contribution to disease onset[J]J Immunol Res, 2019, 4813795.
doi: 10.1155/2019/4813795
[22]   DE VRIES J E. Immunosuppressive and anti-inflammatory properties of interleukin 10[J]Ann Med, 1995, 27( 5): 537-541.
doi: 10.3109/07853899509002465
[23]   MORETTA L, LOCATELLI F. Innate lymphoid cells in normal and disease: an introductory overview[J]Immunol Lett, 2016, 1.
doi: 10.1016/j.imlet.2016.07.008
[24]   CHIOSSONE L, DUMAS P Y, VIENNE M, et al.Natural killer cells and other innate lymphoid cells in cancer[J]Nat Rev Immunol, 2018, 18( 11): 671-688.
doi: 10.1038/s41577-018-0061-z
[25]   BERNINK J H, PETERS C P, MUNNEKE M, et al.Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues[J]Nat Immunol, 2013, 14( 3): 221-229.
doi: 10.1038/ni.2534
[26]   BRITO-ZERóN P, BALDINI C, BOOTSMA H, et al.Sj?gren syndrome[J]Nat Rev Dis Primers, 2016, 2( 1): 16047.
doi: 10.1038/nrdp.2016.47
[27]   李鑫, 吴刚, 金向楠, 等. Ⅱ型固有淋巴样细胞(ILC2)通过分泌IL-13减缓类风湿性关节炎患者的发病进程[J]. 细胞与分子免疫学杂志, 2020, 36(9): 815-820
LI Xin, WU Gang, JIN Xiangnan, et al. Group 2 innate lymphoid cells (ILC2) relieves pathogenesis of rheumatoid arthritis by secreting IL-13[J]. Chinese Journal of Cellular and Molecular Immunology, 2020, 36(9): 815-820. (in Chinese)
[28]   CAI T, QIU J, JI Y, et al.IL-17-producing ST2+ group 2 innate lymphoid cells play a pathogenic role in lung inflammation[J]J Allergy Clin Immunol, 2019, 143( 1): 229-244.e9.
doi: 10.1016/j.jaci.2018.03.007
[29]   CICCIA F, GUGGINO G, RIZZO A, et al.Interleukin (IL)-22 receptor 1 is over-expressed in primary Sj?gren’s syndrome and Sj?gren-associated non-Hodgkin lymphomas and is regulated by IL-18[J]Clin Exp Immunol, 2015, 181( 2): 219-229.
doi: 10.1111/cei.12643
[30]   MAGRI G, MIYAJIMA M, BASCONES S, et al.Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells[J]Nat Immunol, 2014, 15( 4): 354-364.
doi: 10.1038/ni.2830
[31]   DARIDON C, DEVAUCHELLE V, HUTIN P, et al.Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sj?gren’s syndrome[J]Arthritis Rheum, 2007, 56( 4): 1134-1144.
doi: 10.1002/art.22458
[32]   POLI A, MICHEL T, THéRéSINE M, et al.CD56 bright natural killer (NK) cells: an important NK cell subset[J]Immunology, 2009, 126( 4): 458-465.
doi: 10.1111/j.1365-2567.2008.03027.x
[33]   PONTARINI E, SCIACCA E, GRIGORIADOU S, et al.NKp30 receptor upregulation in salivary glands of Sj?gren’s syndrome characterizes ectopic lymphoid structures and is restricted by rituximab treatment[J]Front Immunol, 2021, 706737.
doi: 10.3389/fimmu.2021.706737
[34]   CAPRIO M, NEWFELL B G, LA SALA A, et al.Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion[J]Circ Res, 2008, 102( 11): 1359-1367.
doi: 10.1161/CIRCRESAHA.108.174235
[35]   B?OCHOWIAK K J, OLEWICZ-GAWLIK A, TRZYBULSKA D, et al.Serum ICAM-1, VCAM-1 and E-selectin levels in patients with primary and secondary Sj?gren’s syndrome[J]Adv Clin Exp Med, 2017, 26( 5): 835-842.
doi: 10.17219/acem/61434
[36]   OHNO A, MITSUI T, ENDO I, et al. Dermatomyositis associated with Sj?gren’s syndrome: VEGF involvement in vasculitis. Clin Neuropathol. 2004, 23(4): 178-182
[37]   MEERMEIER E W, HARRIFF M J, KARAMOOZ E, et al.MAIT cells and microbial immunity[J]Immunol Cell Biol, 2018, 96( 6): 607-617.
doi: 10.1111/imcb.12022
[38]   WANG J J, MACARDLE C, WEEDON H, et al.Mucosal-associated invariant T cells are reduced and functionally immature in the peripheral blood of primary Sj?gren’s syndrome patients[J]Eur J Immunol, 2016, 46( 10): 2444-2453.
doi: 10.1002/eji.201646300
[39]   GUGGINO G, DI LIBERTO D, LO PIZZO M, et al.IL-17 polarization of MAIT cells is derived from the activation of two different pathways[J]Eur J Immunol, 2017, 47( 11): 2002-2003.
doi: 10.1002/eji.201747140
[40]   DODINGTON D W, DESAI H R, WOO M. JAK/STAT-emerging players in metabolism[J]Trends Endocrinol Metab, 2018, 29( 1): 55-65.
doi: 10.1016/j.tem.2017.11.001
[41]   CHARRAS A, ARVANITI P, LE DANTEC C, et al.JAK inhibitors suppress innate epigenetic reprogramming: a promise for patients with Sj?gren’s syndrome[J]Clinic Rev Allerg Immunol, 2020, 58( 2): 182-193.
doi: 10.1007/s12016-019-08743-y
[42]   PENG Y, LUO X, CHEN Y, et al.LncRNA and mRNA expression profile of peripheral blood mononuclear cells in primary Sj?gren’s syndrome patients[J]Sci Rep, 2020, 10( 1): 19629.
doi: 10.1038/s41598-020-76701-2
[43]   PERTOVAARA M, SILVENNOINEN O, ISOM?KI P. Cytokine-induced STAT1 activation is increased in patients with primary Sj?gren’s syndrome[J]Clin Immunol, 2016, 60-67.
doi: 10.1016/j.clim.2016.03.010
[44]   CHARRAS A, ARVANITI P, LE DANTEC C, et al.JAK inhibitors and oxidative stress control[J]Front Immunol, 2019, 2814.
doi: 10.3389/fimmu.2019.02814
[45]   PONTARINI E, MURRAY-BROWN W J, CROIA C, et al.Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sj?gren’s syndrome with ectopic germinal centres and MALT lymphoma[J]Ann Rheum Dis, 2020, 79( 12): 1588-1599.
doi: 10.1136/annrheumdis-2020-217646
[46]   LONG D, CHEN Y J, WU H J, et al.Clinical significance and immunobiology of IL-21 in autoimmunity[J]J Autoimmunity, 2019, 1-14.
doi: 10.1016/j.jaut.2019.01.013
[47]   BARRERA M J, AGUILERA S, CASTRO I, et al.Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sj?gren’s syndrome[J]Rheumatology, 2021, 60( 4): 1951-1962.
doi: 10.1093/rheumatology/keaa670
[48]   LEE J, LEE J, KWOK S K, et al.JAK‐1 inhibition suppresses interferon‐induced BAFF production in human salivary gland[J]Arthritis Rheumatol, 2018, 70( 12): 2057-2066.
doi: 10.1002/art.40589
[49]   AQRAWI L A, IVANCHENKO M, BJ?RK A, et al.Diminished CXCR5 expression in peripheral blood of patients with Sj?gren’s syndrome may relate to both genotype and salivary gland homing[J]Clin Exp Immunol, 2018, 192( 3): 259-270.
doi: 10.1111/cei.13118
[50]   IKAI K, SAKAI M, MINAGI H O, et al.ΔNp63 is upregulated during salivary gland regeneration following duct ligation and irradiation in mice[J]FEBS Lett, 2020, 594( 19): 3216-3226.
doi: 10.1002/1873-3468.13896
[51]   CHEN X, ZHANG P, LIU Q, et al.Alleviating effect of paeoniflorin-6′-O-benzene sulfonate in antigen-induced experimental Sj?gren’s syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway[J]Int Immunopharmacol, 2020, 106199.
doi: 10.1016/j.intimp.2020.106199
[52]   FU J, SHI H, CAO N, et al.Toll-like receptor 9 signaling promotes autophagy and apoptosis via divergent functions of the p38/JNK pathway in human salivary gland cells[J]Exp Cell Res, 2019, 375( 2): 51-59.
doi: 10.1016/j.yexcr.2018.12.027
[53]   PARK E, KIM D, LEE S M, et al.Inhibition of lysophosphatidic acid receptor ameliorates Sj?gren’s syndrome in NOD mice[J]Oncotarget, 2017, 8( 16): 27240-27251.
doi: 10.18632/oncotarget.15916
[54]   SISTO M, LORUSSO L, INGRAVALLO G, et al.TGFβ1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sj?gren’s syndrome[J]Lab Invest, 2020, 100( 6): 824-836.
doi: 10.1038/s41374-020-0373-z
[55]   WILLIAMS A E G, CHOI K, CHAN A L, et al.Sj?gren’s syndrome-associated microRNAs in CD14+ monocytes unveils targeted TGFβ signaling[J]Arthritis Res Ther, 2016, 18( 1): 95.
doi: 10.1186/s13075-016-0987-0
[56]   FRUMAN D A, CHIU H, HOPKINS B D, et al.The PI3K pathway in human disease[J]Cell, 2017, 170( 4): 605-635.
doi: 10.1016/j.cell.2017.07.029
[57]   CAI Y, SUN R, WANG R, et al.The activation of Akt/mTOR pathway by bleomycin in epithelial-to-mesenchymal transition of human submandibular gland cells: a treatment mechanism of bleomycin for mucoceles of the salivary glands[J]Biomed Pharmacother, 2017, 109-115.
doi: 10.1016/j.biopha.2017.02.098
[58]   BLOKLAND S L M, HILLEN M R, WICHERS C G K, et al.Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sj?gren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?[J/OL]RMD Open, 2019, 5( 1): e000701.
doi: 10.1136/rmdopen-2018-000701
[59]   WANG J, WANG X, WANG L, et al.MiR-let-7d-3p regulates IL-17 expression through targeting AKT1/mTOR signaling in CD4+T cells[J]In Vitro Cell Dev Biol Anim, 2020, 56( 1): 67-74.
doi: 10.1007/s11626-019-00409-5
[60]   SOYPA?AC? Z, GüMü? Z Z, ?AKALO?LU F, et al.Role of the mTOR pathway in minor salivary gland changes in Sjogren’s syndrome and systemic sclerosis[J]Arthritis Res Ther, 2018, 20( 1): 170.
doi: 10.1186/s13075-018-1662-4
[61]   SILVER N, PROCTOR G B, ARNO M, et al.Activation of mTOR coincides with autophagy during ligation-induced atrophy in the rat submandibular gland[J/OL]Cell Death Dis, 2010, 1( 1): e14.
doi: 10.1038/cddis.2009.12
[62]   LU X, LI N, ZHAO L, et al.Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype[J]Exp Eye Res, 2020, 107905.
doi: 10.1016/j.exer.2019.107905
[63]   KYTHREOTOU A, SIDDIQUE A, MAURI F A, et al.PD-L1[J]J Clin Pathol, 2018, 71( 3): 189-194.
doi: 10.1136/jclinpath-2017-204853
[64]   CHEMNITZ J M, PARRY R V, NICHOLS K E, et al.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation[J]J Immunol, 2004, 173( 2): 945-954.
doi: 10.4049/jimmunol.173.2.945
[65]   LITAK J, MAZUREK M, GROCHOWSKI C, et al.PD-L1/PD-1 axis in glioblastoma multiforme[J]Int J Mol Sci, 2019, 20( 21): 5347.
doi: 10.3390/ijms20215347
[66]   KOBAYASHI M, KAWANO S, HATACHI S, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sj?gren’s syndrome[J]. J Rheumatol. 2005, 32(11): 2156-2163
[67]   CHEN Y, WANG Y, XU L, et al.Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sj?gren’s syndrome[J]Int J Rheum Dis, 2019, 22( 2): 200-206.
doi: 10.1111/1756-185X.13391
[68]   XIA L, LIU Y, WANG Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions[J]Oncol, 2019, 24( S1): 31.
doi: 10.1634/theoncologist.2019-IO-S1-s05
[69]   AKIRA S, UEMATSU S, TAKEUCHI O. Pathogen recognition and innate immunity[J]Cell, 2006, 124( 4): 783-801.
doi: 10.1016/j.cell.2006.02.015
[70]   KIRIPOLSKY J, ROMANO R A, KASPEREK E M, et al.Activation of myd88-dependent TLRs mediates local and systemic inflammation in a mouse model of primary Sj?gren’s syndrome[J]Front Immunol, 2020, 2963.
doi: 10.3389/fimmu.2019.02963
[71]   KIRIPOLSKY J, MCCABE L G, GAILE D P, et al.Myd88 is required for disease development in a primary Sj?gren’s syndrome mouse model[J]J Leukoc Biol, 2017, 102( 6): 1411-1420.
doi: 10.1189/jlb.3A0717-311R
[72]   KARLSEN M, JONSSON R, BRUN J G, et al.TLR-7 and -9 stimulation of peripheral blood B cells indicate altered TLR signalling in primary Sj?gren’s syndrome patients by increased secretion of cytokines[J]Scand J Immunol, 2015, 82( 6): 523-531.
doi: 10.1111/sji.12368
[73]   BAUMANN C L, ASPALTER I M, SHARIF O, et al.CD14 is a coreceptor of Toll-like receptors 7 and 9[J]J Exp Med, 2010, 207( 12): 2689-2701.
doi: 10.1084/jem.20101111
[74]   CHEN L, CHEN P, LIU J, et al.Sargassum fusiforme polysaccharide SFP-F2 activates the NF-κB signaling pathway via CD14/IKK and P38 axes in RAW264.7 cells[J]Mar Drugs, 2018, 16( 8): 264.
doi: 10.3390/md16080264
[75]   YOSHIMOTO K, SUZUKI K, TAKEI E, et al.Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sj?gren’s syndrome[J]Arthritis Res Ther, 2020, 22( 1): 157.
doi: 10.1186/s13075-020-02249-1
[76]   CARRILLO-BALLESTEROS F J, PALAFOX-SáNCHEZ C A, FRANCO-TOPETE R A, et al.Expression of BAFF and BAFF receptors in primary Sj?gren’s syndrome patients with ectopic germinal center-like structures[J]Clin Exp Med, 2020, 20( 4): 615-626.
doi: 10.1007/s10238-020-00637-0
[77]   SALAZAR-CAMARENA D C, ORTíZ-LAZARENO P, MARíN-ROSALES M, et al.BAFF-R and TACI expression on CD3+ T cells: interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus[J]Cytokine, 2019, 115-127.
doi: 10.1016/j.cyto.2018.11.008
[78]   FU J, SHI H, ZHAN T, et al.BST-2/Tetherin is involved in BAFF-enhanced proliferation and survival via canonical NF-κB signaling in neoplastic B-lymphoid cells[J]Exp Cell Res, 2021, 398( 1): 112399.
doi: 10.1016/j.yexcr.2020.112399
[79]   DERUDDER E, HERZOG S, LABI V, et al.Canonical NF-κB signaling is uniquely required for the long-term persistence of functional mature B cells[J]Proc Natl Acad Sci U S A, 2016, 113( 18): 5065-5070.
doi: 10.1073/pnas.1604529113
[80]   GANDOLFO S, DE VITA S. Double anti-B cell and anti-BAFF targeting for the treatment of primary Sj?gren’s syndrome[J]. Clin Exp Rheumatol. 2019, 37 Suppl 118(3): 199-208
[81]   DECKER T, MüLLER M, STOCKINGER S. The yin and yang of type Ⅰ interferon activity in bacterial infection[J]Nat Rev Immunol, 2005, 5( 9): 675-687.
doi: 10.1038/nri1684
[82]   BODEWES I L A, HUIJSER E, VAN HELDEN-MEEUWSEN C G, et al.TBK1: a key regulator and potential treatment target for interferon positive Sj?gren’s syndrome, systemic lupus erythematosus and systemic sclerosis[J]J Autoimmunity, 2018, 97-102.
doi: 10.1016/j.jaut.2018.02.001
[83]   BODEWES I L A, BJ?RK A, VERSNEL M A, et al.Innate immunity and interferons in the pathogenesis of Sj?gren’s syndrome[J]Rheumatology, 2021, 60( 6): 2561-2573.
doi: 10.1093/rheumatology/key360
[84]   MARIA N I, STEENWIJK E C, IJPMA A S, et al.Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-Ⅰ and MDA5 in interferon-positive and interferon-negative patients with primary Sj?gren’s syndrome[J]Ann Rheum Dis, 2017, 76( 4): 721-730.
doi: 10.1136/annrheumdis-2016-209589
[85]   IVASHKIV L B, DONLIN L T. Regulation of type Ⅰ interferon responses[J]Nat Rev Immunol, 2014, 14( 1): 36-49.
doi: 10.1038/nri3581
[86]   MAVRAGANI C P. Mechanisms and new strategies for primary Sj?gren’s syndrome[J]Annu Rev Med, 2017, 68( 1): 331-343.
doi: 10.1146/annurev-med-043015-123313
[87]   DAVIES R, HAMMENFORS D, BERGUM B, et al.Aberrant cell signalling in PBMCs upon IFN‐α stimulation in primary Sj?gren’s syndrome patients associates with type Ⅰ interferon signature[J]Eur J Immunol, 2018, 48( 7): 1217-1227.
doi: 10.1002/eji.201747213
[88]   APOSTOLOU E, KAPSOGEORGOU E K, KONSTA O D, et al.Expression of type Ⅲ interferons (IFNλs) and their receptor in Sj?gren’s syndrome[J]Clin Exp Immunol, 2016, 186( 3): 304-312.
doi: 10.1111/cei.12865
[89]   THOMPSON N, ISENBERG D A, JURY E C, et al.Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sj?gren’s syndrome[J]Rheumatology, 2016, 55( 9): 1548-1555.
doi: 10.1093/rheumatology/kev420
[90]   DE OLIVEIRA F R, FANTUCCI M Z, ADRIANO L, et al.Neurological and inflammatory manifestations in Sj?gren’s syndrome: the role of the kynurenine metabolic pathway[J]Int J Mol Sci, 2018, 19( 12): 3953.
doi: 10.3390/ijms19123953
[1] LU Xixuan,BAO Lisha,PAN Zongfu,GE Minghua. Immunotherapy for anaplastic thyroid carcinoma: the present and future[J]. J Zhejiang Univ (Med Sci), 2021, 50(6): 675-684.
[2] QIAN Chenhong,JIANG Liehao,XU Shiying,WANG Jiafeng,TAN Zhuo,XIN Ying,GE Minghua. Advances in targeted therapy for anaplastic thyroid carcinoma[J]. J Zhejiang Univ (Med Sci), 2021, 50(6): 685-693.
[3] ZHOU Jing,WANG Yan,XU Enping. Research progress on application of microhaplotype in forensic genetics[J]. J Zhejiang Univ (Med Sci), 2021, 50(6): 777-782.
[4] MA Lijuan,WU Shuang,ZHANG Kai,TIAN Mei,ZHANG Hong. Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases[J]. J Zhejiang Univ (Med Sci), 2021, 50(5): 666-673.
[5] XUAN Zixue,ZHANG Yiwen,PAN Zongfu,ZHENG Xiaowei,HUANG Ping. Natural medicinal ingredients induce tumor ferroptosis and related mechanisms[J]. J Zhejiang Univ (Med Sci), 2021, 50(5): 601-606.
[6] QU Wenzheng,ZHUANG Yingliang,LI Xuekun. The roles of epigenetic modifications in neurodegenerative diseases[J]. J Zhejiang Univ (Med Sci), 2021, 50(5): 642-650.
[7] SUN Qi,CAO Wei,LUO Jianhong. The roles of GluN3-containing N-methyl-D-aspartate receptor in central nerve system[J]. J Zhejiang Univ (Med Sci), 2021, 50(5): 651-658.
[8] SHI Jianrong,MA Wangqian,TANG Huifang. Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment[J]. J Zhejiang Univ (Med Sci), 2021, 50(5): 659-665.
[9] TANG Yue,KONG Yuanyuan. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 514-523.
[10] LIU Fei,FENG Chunyue,MAO Jianhua,FU Haidong. New-onset and relapsing glomerular diseases related to COVID-19 vaccination[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 524-528.
[11] HAN Lianshu. Genetic screening techniques and diseases for neonatal genetic diseases[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 429-435.
[12] HU Mangsha,WEI Shuli,ZHOU Wuyuan,WANG Pingli. Research progress on neonatal Fc receptor and its application[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 537-544.
[13] HU Jingyi,WANG Qingqing,LIU Yang. Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 396-402.
[14] GE Yingzhou,LIU Xinmei,HUANG Hefeng. Advances in the role of silence information regulator family in pathological pregnancy[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 335-344.
[15] WANG Jintao,HUANG Lei,WEI Lili,CHEN Wei. Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer’s disease[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 383-389.